HomePharmacologyAntiplatelet

Antiplatelet

View Category

Acute coronary syndromes

ESC 2021 | ISAR-REACT 5: Prasugrel Superior to Ticagrelor in ACS across Kidney Function Spectrum

When we have to choose between two potent P2Y12 receptor inhibitors for a patient undergoing ACS with...
solaci -
Learn More
Antiplatelet

ESC 2021 | MASTER DAPT: Dual Antiplatelet Therapy After Coronary Angioplasty in Patients at High Bleeding Risk

Courtesy of Dr. José Álvarez. In patients at high bleeding risk with drug-eluting stents, the duration of dual...
solaci -
Learn More
Acute coronary syndromes

Dual Antiaggregation De-Escalation: A New Paradigm?

De-escalating dual antiaggregation could be the most effective strategy after acute coronary syndrome seeing as it prevents...
solaci -
Learn More
Acute coronary syndromes

The Role of Aspirin after the TWILIGHT-ACS

This analysis corroborates the potential benefit of ticagrelor monotherapy following a short period of dual antiaggregation (DAPT)...
solaci -
Learn More
Acute coronary syndromes

Ticagrelor or Prasugrel for Acute Patients Who Undergo Angioplasty

We are still asking the same question: ticagrelor or prasugrel? With narrow margins between these drugs in...
solaci -
Learn More
Antiplatelet

AAS vs DAPT post TAVI: Meta-Analysis of Randomized Studies

Aspirin monotherapy (ASA) reduced the combined risk of thrombotic and bleeding events compared against dual antiplatelet therapy...
solaci -
Learn More
Antiplatelet

DAPT vs. Monotherapy: The Dilemma Remains After Surgery

Patients who undergo myocardial revascularization surgery and are discharged on dual antiplatelet therapy (DAPT)—aspirin plus clopidogrel—have a...
solaci -
Learn More
Antiplatelet

Post TAVR Aspirin vs. Clopidogrel: Conflicting Findings and Guidelines

One month ago we shared a meta-analysis stating aspirin (ASA) as the best antiplatelet following TAVR vs....
solaci -
Learn More